Primary myelofibrosis (PMF) is a myeloproliferative neoplasm in which clonal proliferation of hematopoietic stem cells and bone marrow fibrosis coexist.1 Patients may eventually die due to leukemic progression, which occurs in up to 20% of cases, or because of cardiovascular comorbidities or cytopenia, which causes susceptibility to infections and bleeding.
Accurso, V., Santoro, M., Mancuso, S., Napolitano, M., Di Piazza, F., Russo, A., et al. (2019). Efficacy of ruxolitinib retreatment in a patient with high-risk myelofibrosis using the international prognostic scoring system. DRUGS IN CONTEXT, 8 [10.7573/dic.212569].
Efficacy of ruxolitinib retreatment in a patient with high-risk myelofibrosis using the international prognostic scoring system
Santoro, Marco;Mancuso, Salvatrice;Napolitano, Mariasanta;Di Piazza, Florinda;Russo, Antonio;Siragusa, Sergio
2019-01-01
Abstract
Primary myelofibrosis (PMF) is a myeloproliferative neoplasm in which clonal proliferation of hematopoietic stem cells and bone marrow fibrosis coexist.1 Patients may eventually die due to leukemic progression, which occurs in up to 20% of cases, or because of cardiovascular comorbidities or cytopenia, which causes susceptibility to infections and bleeding.
File in questo prodotto:
| File | Dimensione | Formato | |
|---|---|---|---|
|
Articolo Ruxo.pdf
accesso aperto
Tipologia:
Versione Editoriale
Dimensione
221.23 kB
Formato
Adobe PDF
|
221.23 kB | Adobe PDF | Visualizza/Apri |
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
